Binds A Receptor (e.g., Transferrin Receptor, Fc Receptor, Dihydropyridine Receptor, Il-2 Receptor, Etc.) Patents (Class 435/334)
-
Publication number: 20120148600Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: November 28, 2011Publication date: June 14, 2012Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Publication number: 20120148607Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: ApplicationFiled: November 3, 2011Publication date: June 14, 2012Applicant: ARGEN-X B.V.Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Publication number: 20120135010Abstract: An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance, is provided.Type: ApplicationFiled: December 2, 2011Publication date: May 31, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
-
Patent number: 8187826Abstract: The invention relates to methods and kits for the quantitative analysis of in vivo mutation frequencies of the Pig-A gene in individuals exposed to a genotoxicant, particularly using peripheral blood samples of vertebrates.Type: GrantFiled: June 12, 2009Date of Patent: May 29, 2012Assignee: Litron Laboratories, Ltd.Inventor: Stephen D. Dertinger
-
Patent number: 8178496Abstract: The present invention provides a synthetic regulator of glutamate receptor function, which regulator is a light-sensitive (photoreactive) regulator. The present invention further provides a light-regulated glutamate receptor that includes a subject synthetic regulator non-covalently associated with the glutamate receptor. Also provided are cells and membranes comprising a subject light-regulated glutamate receptor. The present invention further provides methods of modulating glutamate receptor function, involving use of light. The present invention further provides methods of identifying agents that modulate glutamate receptor function.Type: GrantFiled: December 18, 2008Date of Patent: May 15, 2012Assignee: The Regents of the University of CaliforniaInventors: Dirk Trauner, Ehud Y. Isacoff, Matthew Volgraf, Pablo Ignacio Gorostiza Langa
-
Publication number: 20120114704Abstract: The present invention provides antibodies or antigen-binding fragments thereof that specifically hind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.Type: ApplicationFiled: March 23, 2010Publication date: May 10, 2012Inventor: Elena Feinstein
-
Publication number: 20120114659Abstract: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.Type: ApplicationFiled: November 17, 2009Publication date: May 10, 2012Applicants: MORPHOSYS AG, BOEHRINGER INGELHEIM PHARMACEUTICALS INC.Inventors: Alisa Waterman, Daniel Rajotte, Tobias Litzenburger, Alexandra Kraus
-
Patent number: 8173424Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: December 16, 2010Date of Patent: May 8, 2012Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Patent number: 8173372Abstract: The detection of endothelial cell antibodies has been proven clinically important for successful organ transplantation. Disclosed are methods of isolating Tie-2+ and CD34? precursor endothelial cells for use in donor-specific crossmatching.Type: GrantFiled: May 16, 2003Date of Patent: May 8, 2012Assignee: AbSorber ABInventor: Suchitra Sumitran-Holgersson
-
Publication number: 20120107234Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.Type: ApplicationFiled: November 1, 2011Publication date: May 3, 2012Inventors: Mikkel W. PEDERSEN, Ida K. CHRISTENSEN, Johan LANTTO, Helle JACOBSEN, Michael KRAGH
-
Publication number: 20120093826Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.Type: ApplicationFiled: March 5, 2010Publication date: April 19, 2012Applicants: OXFORD BIOTHERAPEUTICS LTD, MEDAREX, INC.Inventors: Jonathan Alexander Terrett, Heidi Leblanc, Haichun Huang, Erika Meaddough, Chin Pan, Bingliang Chen, Chetana Rao-Naik
-
Patent number: 8153134Abstract: Antibodies to human MDL-1 are provided, as well as uses thereof, e.g., in treatment of immune disorders, in particular, infectious diseases and sepsis.Type: GrantFiled: April 21, 2008Date of Patent: April 10, 2012Assignee: Schering CorporationInventors: Michael E. Bigler, Paul G. Heyworth, Joseph H. Phillips, Leonard G. Presta
-
Patent number: 8153765Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.Type: GrantFiled: October 16, 2007Date of Patent: April 10, 2012Assignee: Sanof AventisInventors: Peter U. Park, Laura M. Bartle, Anna Skaletskaya, Viktor Golmakher, Daniel Tavares, Jutta Deckert, Vincent Mikol, Veronique Blanc
-
Publication number: 20120077207Abstract: The present invention discloses a method for assaying the binding of L104EA29YIg to a receptor. The receptor is preferably CD86 or CD80. The present invention also discloses antibodies to be used in the assay, as well as hybridomas expressing the antibodies.Type: ApplicationFiled: January 7, 2009Publication date: March 29, 2012Inventors: Catherine A. Fleener, Robert M. Townsend, Francisco Leon
-
Patent number: 8143058Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: GrantFiled: October 13, 2010Date of Patent: March 27, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
-
Patent number: 8143056Abstract: The invention relates to new polypeptides in isolated form belonging to a subfamily of the human immunoglobulin superfamily, which polypeptide shows at least 70% sequence homology with the amino acid sequence of the murine Confluency Regulated Adhesion Molecules 1 or 2 (CRAM-1 or CRAM-2) as depicted in FIG. 3, upper and second row, respectively, and antibodies thereto as well as their use in treatment of inflammation and tumors.Type: GrantFiled: February 10, 2010Date of Patent: March 27, 2012Assignee: Merck Serono SAInventors: Beat Albert Imhof, Michel Aurrand-Lions
-
Publication number: 20120034221Abstract: The present invention is directed to the production and use of monoclonal antibodies, or antigen binding fragments thereof, that specifically bind the T cell antigen receptor (TCR) and their use for immunomodulation. In preferred embodiments, the antibody or antigen binding fragment of the invention specifically binds the constant region of the ? chain of the TCR, or otherwise specifically binds the ? chain regardless of TCR clonal origin (i.e., is pan specific for TCR). The antibodies of the invention may be used, for example, in immunosuppressive therapies for transplant maintenance and the treatment of autoimmune diseases, and/or as targeting molecules for use in the treatment of T-cell malignancies.Type: ApplicationFiled: October 14, 2011Publication date: February 9, 2012Applicant: MACROGENICS INC.Inventors: Ezio Bonvini, Leslie S. Johnson, Nadine Tuaillon, Ling Huang
-
Publication number: 20120034237Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: July 29, 2011Publication date: February 9, 2012Applicant: AMGEN INC.Inventors: Thomas C. BOONE, Jonathan D. OLINER
-
Publication number: 20120034232Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.Type: ApplicationFiled: May 5, 2011Publication date: February 9, 2012Applicant: Innate PharmaInventors: Laurent Gauthier, Catherine Massacrier, Yannis Morel, Carine Paturel
-
Publication number: 20120027773Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.Type: ApplicationFiled: July 6, 2011Publication date: February 2, 2012Inventors: Kerry Whalen, Steve Botega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, JR., Jeno Gyuris
-
Publication number: 20120027756Abstract: Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.Type: ApplicationFiled: September 23, 2011Publication date: February 2, 2012Applicant: IRM LLCInventors: Liqun DONG, Marc NASOFF
-
Publication number: 20120020985Abstract: The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease.Type: ApplicationFiled: March 31, 2010Publication date: January 26, 2012Applicant: Medical Research CouncilInventors: Andrew Neil James McKenzie, Daniel Neill
-
Patent number: 8101381Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides polynucleotides, vectors, cells, and methods of production related to a new human cytokine receptor designated as “Zcytor16.Type: GrantFiled: July 8, 2010Date of Patent: January 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
-
Patent number: 8101365Abstract: The invention provides anti-EphB4 antibodies, and compositions comprising and methods of using these antibodies.Type: GrantFiled: January 4, 2007Date of Patent: January 24, 2012Assignee: Genentech, Inc.Inventors: Yan Wu, Minhong Yan
-
Patent number: 8101179Abstract: A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in culture of the CD20 antigen expressing cells without effector cells. The anti-CD20 monoclonal antibody is incorporated into chimeric anti-CD20 monoclonal antibodies in which the amino acid sequences of the variable regions of the anti-CD20 monoclonal antibody and the amino acid sequences of the constant regions of human immunoglobulin are fused. Also a humanized anti-CD20 monoclonal antibody is described which includes all of the variable region CDRs of the H chain of the anti-CD20 monoclonal antibody and all of the variable region CDRs of the L chain of the anti-CD20 monoclonal antibody and an amino acid sequence of human immunoglobulin. A nucleotide sequence encoding the amino acid sequence of the chimeric or humanized anti-CD20 monoclonal antibody can be expressed in mammalian cells.Type: GrantFiled: March 31, 2006Date of Patent: January 24, 2012Assignee: Biomedics Inc.Inventors: Masanori Numazaki, Tetsuo Nakamura, Sadakazu Usuda, Eduardo A. Padlan
-
Publication number: 20120009181Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: ApplicationFiled: February 24, 2011Publication date: January 12, 2012Inventors: Olga AB, Daniel TAVARES, Lingyun RUI, Gillian PAYNE, Viktor S. GOLDMAKHER
-
Patent number: 8093010Abstract: The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular Mab H33, to soluble JAM-C and JAM-B and to small molecules.Type: GrantFiled: October 29, 2009Date of Patent: January 10, 2012Assignee: Merck Serono S.A.Inventors: Beat A. Imhof, Michel Aurrand-Lions
-
Patent number: 8093045Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: GrantFiled: September 13, 2007Date of Patent: January 10, 2012Assignee: Abbott LaboratoriesInventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, David Chang Yu-Hsiang, Thomas Seewoester
-
Patent number: 8092804Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: GrantFiled: December 18, 2008Date of Patent: January 10, 2012Assignee: MedImmune LimitedInventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Publication number: 20120005767Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: June 27, 2011Publication date: January 5, 2012Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose R. Corvalan, Michael Gallo
-
Patent number: 8088617Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.Type: GrantFiled: January 24, 2008Date of Patent: January 3, 2012Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Aaron Sato, Maureen Fitch-Bruhns
-
Publication number: 20110318368Abstract: The present invention relates to an anti-human ?9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ?9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening for a compound that inhibits the activity of human ?9 integrin.Type: ApplicationFiled: February 23, 2009Publication date: December 29, 2011Inventors: Shigeyuki Kon, Toshimitsu Uede
-
Publication number: 20110318758Abstract: The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer.Type: ApplicationFiled: August 4, 2008Publication date: December 29, 2011Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENTInventors: Natalie Sutkowski, Semyon Rubinchik
-
Publication number: 20110311552Abstract: Means and methods for the diagnosis, characterization, prognosis and treatment of cancer, specifically targeting cancer stem cells are disclosed Provided is an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth, and a method of treating cancer comprising administering said antibody to a subject.Type: ApplicationFiled: July 8, 2009Publication date: December 22, 2011Inventors: Austin L. Gurney, Timothy Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Publication number: 20110311449Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: February 10, 2011Publication date: December 22, 2011Applicant: AFFITECH RESEARCH ASInventors: Anita Kavlie, Sergej Michailovic Kiprijanov
-
Patent number: 8080415Abstract: The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.Type: GrantFiled: July 21, 2009Date of Patent: December 20, 2011Assignee: Eureka Therapeutics, Inc.Inventors: Cheng Liu, Jingyi Xiang, Su Yan, Pei Wang, Wei Chan Tai
-
Publication number: 20110305687Abstract: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.Type: ApplicationFiled: May 11, 2011Publication date: December 15, 2011Inventors: Zhigang Weng, William M. Winston, JR., Ailin Bai, Kristan Meetze, Solly Weiler, Ting Chen, Jeno Gyuris
-
Patent number: 8071096Abstract: The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation.Type: GrantFiled: January 24, 2003Date of Patent: December 6, 2011Assignee: G2 Therapies LtdInventor: Charles Reay MacKay
-
Publication number: 20110296544Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: May 16, 2011Publication date: December 1, 2011Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Alqun Li, Tao He, Ian McCaffery
-
Patent number: 8062860Abstract: The present invention relates a method for the enumeration of in vivo gene mutation. The method utilizes differential staining of GPI-anchor deficient erythrocyte populations to distinguish between wild-type and pig-a gene mutants. Quantitative analyses can be conducted on erythrocytes and/or reticulocytes, and is based upon fluorescent emission and light scatter following exposure to an excitatory light source. Counting of mutant erythrocytes or reticulocytes relative to the number of total erythrocytes or reticulocytes can be used to assess the DNA-damaging potential of an exogenous chemical agent, the DNA-damaging potential of an exogenous physical agent, the effects of an exogenous agent which can modify endogenously-induced DNA damage, and the effects of an exogenous agent which can modify exogenously-induced DNA damage. Kits for practicing the invention are also disclosed.Type: GrantFiled: October 6, 2010Date of Patent: November 22, 2011Assignee: Litron Laboratories, Ltd.Inventor: Stephen D. Dertinger
-
Publication number: 20110281348Abstract: The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy.Type: ApplicationFiled: May 13, 2011Publication date: November 17, 2011Inventor: Jaume Pons
-
Publication number: 20110280870Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.Type: ApplicationFiled: January 24, 2011Publication date: November 17, 2011Applicant: Genentech, Inc.Inventors: Ralph H. Schwall, Kelly H. Tabor
-
Publication number: 20110274696Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided.Type: ApplicationFiled: August 17, 2009Publication date: November 10, 2011Applicants: AMGEN FREMONT INC., PFIZER INC.Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
-
Publication number: 20110243963Abstract: Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing.Type: ApplicationFiled: November 14, 2008Publication date: October 6, 2011Inventors: Arie Abo, Minke Binners
-
Patent number: 8030023Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.Type: GrantFiled: October 10, 2006Date of Patent: October 4, 2011Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Avi J. Ashkenazi
-
Publication number: 20110236969Abstract: The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods.Type: ApplicationFiled: March 21, 2011Publication date: September 29, 2011Applicant: Xencor, Inc.Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond
-
Publication number: 20110217695Abstract: The present invention provides polynucleotides for enhanced expression of a target gene such as an immunoglobulin. Methods of expressing a target gene using the polynucleotides of the invention are also covered.Type: ApplicationFiled: November 12, 2009Publication date: September 8, 2011Applicant: Schering CorporationInventor: Deba P. Saha
-
Publication number: 20110217318Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.Type: ApplicationFiled: April 27, 2011Publication date: September 8, 2011Inventors: HIROSHI TAKAYAMA, KAMON SHIRAKAWA, SHOJI FURUSAKO, YOSHITAKA HOSAKA, TOMOKAZU MATSUSUE, KATSUKI NAITOH, YUMI HOTTA, TETSUSHI KAWAHARA, MOTOYASU HONDA
-
Publication number: 20110212110Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.Type: ApplicationFiled: September 15, 2009Publication date: September 1, 2011Inventors: Karine Chemin, Laurent Gauthier, Yannis Morel, Carine Paturel, Agnes Tisserant
-
Patent number: RE43467Abstract: The present invention features a novel combination therapy useful in the treatment of autoimmune disease that increases or maintains the number of functional cells of a predetermined type in a mammal by killing or inactivating autoimmune cells and re-educating the host immune system.Type: GrantFiled: October 25, 2010Date of Patent: June 12, 2012Assignee: The General Hospital CorporationInventor: Denise Faustman